What was the market valuation of the US hyperhidrosis treatment market in 2024?

The market valuation was $211.27 Million in 2024. Read More

What is the projected market valuation for the US hyperhidrosis treatment market by 2035?

The projected valuation for 2035 is $418.2 Million. Read More

What is the expected CAGR for the US hyperhidrosis treatment market during the forecast period 2025 - 2035?

The expected CAGR is 6.4% during the forecast period 2025 - 2035. Read More

Which treatment segment had the highest valuation in 2024?

Botulinum Toxin Injections had the highest valuation at $160.0 Million in 2024. Read More

What are the projected valuations for the Primary Hyperhidrosis segment by 2035?

The projected valuations for Primary Hyperhidrosis are between $127.76 Million and $263.12 Million. Read More

Which end-user segment is expected to show significant growth in the US hyperhidrosis treatment market?

Dermatology Clinics are expected to show significant growth, with valuations projected between $80.0 Million and $160.0 Million. Read More

What is the valuation range for Surgical Treatment in 2024?

The valuation range for Surgical Treatment was between $30.0 Million and $60.0 Million in 2024. Read More

Which company is a key player in the US hyperhidrosis treatment market?

Dermira is one of the key players in the US hyperhidrosis treatment market. Read More

What is the valuation range for Oral Medication in 2024?

The valuation range for Oral Medication was between $25.0 Million and $50.0 Million in 2024. Read More

What is the expected trend for Secondary Generalized Hyperhidrosis segment by 2035?

The expected trend indicates a valuation range for Secondary Generalized Hyperhidrosis between $83.51 Million and $155.08 Million by 2035. Read More

US Hyperhidrosis Treatment Market

ID: MRFR/Pharma/11292-CR

100 Pages

Rahul Gotadki

Last Updated: April 02, 2026

US Hyperhidrosis Treatment Market Research Report: Information By Treatment (Botulinum Toxin Injections, Topical Treatment, Surgical Treatment, Oral Medication and Microwave Therapy), By Type (Primary Hyperhidrosis and Secondary Generalized Hyperhidrosis), By End-User (Dermatology Clinics, Ambulatory Surgery Centers and Payers/Patients), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Life Sciences, BY Treatment (USD Million)
  1. 4.1.1 Botulinum Toxin Injections
  2. 4.1.2 Topical Treatment
  3. 4.1.3 Surgical Treatment
  4. 4.1.4 Oral Medication
  5. 4.1.5 Microwave Therapy
2. 4.2 Life Sciences, BY Type (USD Million)
  1. 4.2.1 Primary Hyperhidrosis
  2. 4.2.2 Secondary Generalized Hyperhidrosis
3. 4.3 Life Sciences, BY End-User (USD Million)
  1. 4.3.1 Dermatology Clinics
  2. 4.3.2 Ambulatory Surgery Centers
  3. 4.3.3 Payers/Patients
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Life Sciences
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Dermira (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Galderma (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Eli Lilly and Company (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Ipsen (FR)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Revance Therapeutics (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Medytox (KR)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Hugel (KR)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Sientra (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TREATMENT
3. 6.3 US MARKET ANALYSIS BY TYPE
4. 6.4 US MARKET ANALYSIS BY END-USER
5. 6.5 KEY BUYING CRITERIA OF LIFE SCIENCES
6. 6.6 RESEARCH PROCESS OF MRFR
7. 6.7 DRO ANALYSIS OF LIFE SCIENCES
8. 6.8 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
9. 6.9 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
10. 6.10 SUPPLY / VALUE CHAIN: LIFE SCIENCES
11. 6.11 LIFE SCIENCES, BY TREATMENT, 2024 (% SHARE)
12. 6.12 LIFE SCIENCES, BY TREATMENT, 2024 TO 2035 (USD Million)
13. 6.13 LIFE SCIENCES, BY TYPE, 2024 (% SHARE)
14. 6.14 LIFE SCIENCES, BY TYPE, 2024 TO 2035 (USD Million)
15. 6.15 LIFE SCIENCES, BY END-USER, 2024 (% SHARE)
16. 6.16 LIFE SCIENCES, BY END-USER, 2024 TO 2035 (USD Million)
17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TREATMENT, 2025-2035 (USD Million)
  2. 7.2.2 BY TYPE, 2025-2035 (USD Million)
  3. 7.2.3 BY END-USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Life Sciences Market Segmentation

Life Sciences By Treatment (USD Million, 2025-2035)

Botulinum Toxin Injections
Topical Treatment
Surgical Treatment
Oral Medication
Microwave Therapy

Life Sciences By Type (USD Million, 2025-2035)

Primary Hyperhidrosis
Secondary Generalized Hyperhidrosis

Life Sciences By End-User (USD Million, 2025-2035)

Dermatology Clinics
Ambulatory Surgery Centers
Payers/Patients

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”